Published in Ann Transl Med on January 01, 2017
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 13.89
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Crypt stem cells as the cells-of-origin of intestinal cancer. Nature (2008) 11.66
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
Scatter factor/hepatocyte growth factor is essential for liver development. Nature (1995) 5.91
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature (1995) 4.68
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell (1994) 4.10
Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A (1987) 3.99
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol (1998) 3.05
Tyrosine kinase receptor indistinguishable from the c-met protein. Nature (1989) 3.00
Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes Dev (2004) 2.99
The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature (2002) 2.99
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature (1998) 2.83
Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A (2004) 2.77
The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol (2002) 2.74
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell (2004) 2.61
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene (2000) 2.52
Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A (1994) 2.36
Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res (1997) 2.30
c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology (2011) 2.27
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell (2001) 2.26
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol (2005) 2.24
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med (2016) 2.18
Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A (1997) 2.12
Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A (2001) 2.08
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A (2009) 2.01
c-Met is essential for wound healing in the skin. J Cell Biol (2007) 1.98
Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A (2003) 1.90
Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol Cell Biol (2006) 1.76
MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol (2012) 1.71
Cross-talk between the proto-oncogenes Met and Ron. Oncogene (2000) 1.71
Crosstalk in Met receptor oncogenesis. Trends Cell Biol (2009) 1.70
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med (2012) 1.69
Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol (2004) 1.64
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Retracted Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J Cell Physiol (2013) 1.62
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res (2000) 1.56
Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene (2002) 1.53
Serum hepatocyte growth factor levels in hepatectomized and nonhepatectomized surgical patients. Gastroenterology (1992) 1.52
Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res (2006) 1.50
Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer (1997) 1.50
A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol (2005) 1.49
The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A (1991) 1.40
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res (2005) 1.35
Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res (2013) 1.35
Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. Genes Dev (1997) 1.31
MET signaling regulates glioblastoma stem cells. Cancer Res (2012) 1.29
Cancer stem cells and glioma. Nat Clin Pract Neurol (2008) 1.29
Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol Cell (2009) 1.28
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One (2013) 1.28
Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer (2006) 1.28
HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell (2004) 1.26
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol (2011) 1.23
HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene (2012) 1.20
Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene (2005) 1.19
Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol (2002) 1.18
Head neck squamous cell carcinoma c-Met⁺ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer (2011) 1.17
Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer (2010) 1.16
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene (1999) 1.14
Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis (2013) 1.13
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res (2012) 1.12
Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncol (2006) 1.12
Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases. PLoS One (2010) 1.10
MET amplification as a potential therapeutic target in gastric cancer. Oncotarget (2013) 1.09
Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene (1998) 1.09
Hepatocyte growth factor-stimulated invasiveness of monocytes. Blood (2000) 1.08
The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther (2013) 1.07
MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res (2011) 1.07
Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell (2009) 1.06
Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol (2001) 1.05
Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia (2009) 1.01
EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. Stem Cell Reports (2015) 1.13
Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell (2015) 1.13
Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges. Oncol Lett (2016) 0.75